

10 Oct 2021 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: will a new oral antiviral be transformative for COVID?; OX40 drugs gain prominence in atopic dermatitis; J&J adds pace to RSV vaccine race; Sarepta leapfrogs Pfizer in DMD gene therapy; and how real-world evidence and randomized trials might go together.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 8 October 2021, including: will a new oral antiviral be transformative for COVID?; OX40 drugs gain prominence in atopic dermatitis; [\*Johnson & Johnson\*](#) adds pace to RSV vaccine race; [\*Sarepta Therapeutics, Inc.\*](#) leapfrogs [\*Pfizer Inc.\*](#) in DMD gene therapy; and how real-world evidence and randomized trials might go together.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [\*Apple Podcasts\*](#), [\*Google Podcasts\*](#), [\*SoundCloud\*](#), [\*TuneIn\*](#) and [\*Spotify Podcasts\*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[\*Merck's Oral Antiviral Data In COVID-19 May Change Pandemic Outlook\*](#)" - Scrip, 1 Oct, 2021.)

(Also see "[\*Sanofi And Amgen Make The Case For OX40 Drugs In Atopic Dermatitis\*](#)" - Scrip, 4 Oct, 2021.)

(Also see "[\*J&J Sets The Pace In Race To \\$10bn RSV Vaccine Market\*](#)" - Scrip, 4 Oct, 2021.)

(Also see "[\*Sarepta Leapfrogs Pfizer In The US, Launching DMD Gene Therapy Pivotal Trial\*](#)" - Scrip, 4 Oct, 2021.)

(Also see "[\*Janssen's Sarich: Randomized Controlled Trials, Real-World Evidence Go Best Together\*](#)" - Scrip, 4 Oct, 2021.)

[Click here to explore this interactive content online](#) ✨